Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
DexCom’s second quarter was marked by robust revenue growth and a significant margin expansion, with management attributing performance to strong global dema...
What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) jumped 10.9% in the morning session after the company reported strong second-quarter res...
Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 ...
DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets.
Worldwide revenue totaled $1.31 billion, co
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q2 CY2026, with sales up 13.1% year on year to $1.31 billion. The compa...
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after the bell. Here’s what to look for. DexCom beat analysts’ revenue ex...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
